Korean J Pediatr Infect Dis.  2001 Nov;8(2):150-159. 10.14776/kjpid.2001.8.2.150.

Persistency of Neutralizing Antibody to Inactivated Mouse Brain Derived Nakayama Japanese Encephalitis Vaccine and Current Observations of Booster Vaccination and Adverse Events

• Sohn YM
• Park JH
• Lee JS
• Roh HO
• Ki M
• Choi BY
• Kim YH

• KMID: 2440180
• DOI: http://doi.org/10.14776/kjpid.2001.8.2.150

Abstract

PURPOSE
We need to reconsider booster vaccination schedule of Japanese encephalitis vaccination. To do that we evaluate the long-term immunogenicity and the incidence of adverse events with inactivated mouse brain derived Nakayama Japanese encephalitis vaccine.
METHODS
We tested neutalizing antibody for 311 elementary school students by plaque reduction neutralizing test(PRNT) at USAMC-AFRIMS(United States Armed Forces Research Institute of Medical Science/Department of Virology). We evaluated vaccine related adverse events by spontaneous reporting prospectively among 15,487 vaccinees who were vaccinated at public health center and 2,277 elementary school students who were immunized previously by a questionnaire and school health record.
RESULTS
According to the time interval from the last booster injection of 311 children, PRNT antibody titers gradually decreased as the interval increased; 239 mIU/mL, 188 mIU/mL, 134 mIU/mL, 49 mIU/mL each at 6, 18, 30, 42 months after the last booster injection. The seropositivity rates were 98%, 99%, 95.6%, 71.4% each at 6, 18, 30, 42 months after the last booster injection. There were 21(0.13%) cases with systemic reactions among 15,487 vaccinees who had visited the hospital by prospective passive reporting system at public health center. According to the questionnaires and school health records in elementary school students, local induration and pain were 17.4% and 14.8%, respectively. Systemic reactions including fever, vomiting, rash were reported in few cases.
CONCLUSION
Biannual booster vaccination that has been recommended so far should not be necessary. Surveillance for adverse events with inactivated mouse brain derived Nakayama vaccine should be strengthened to better assess the number of cases and reactions associated with immunization.

Keyword

JEV; Vaccination; Neutralizing antibody; Persistency

MeSH Terms

Academies and Institutes
Animals
Antibodies, Neutralizing*
Appointments and Schedules
Arm
Asian Continental Ancestry Group*
Brain*
Child
Encephalitis, Japanese*
Exanthema
Fever
Humans
Immunization
Incidence
Mice*
Prospective Studies
Public Health
School Health Services
Vaccination*
Vomiting
Antibodies, Neutralizing

Reference

1). Monath TP. Japanese encephalitis - a plaque of 仕ie orient. N Engl J Med. 1988. 319:641–3.

2). 보건사회부86 급성전염병통계연보. 1986. 1:40–1.

3). 김경호: 백승복: 장경식. 일본뇌염역학조사연구. 국립보건원. 7164. 1967:55–2.

4). 이종문: 고광균. 일본뇌염바이러스에대한HI 항체보유율. 최신의학. 1979. 22:113–9.

5). 예방접종지침서제4판. 대한소아과학회발행1997;93-102.

6). 이종훈: 이연태, 고광균. 한국인의일본뇌염바이러스에대한HI 항체보유율. 대한바이러스학회지. 1980. 10:65–9.

7). 서준석: 조해월: 흥용혜. 일본뇌염바이러스의자연계생환및생태에관한연구. 국립보건원보. 1983. 20:119–23.

8). 이연태, 염병진. 한국일부지역주민에대한일본뇌염바이러스의적혈구응집저지항체에관한연구: 1984– 1985. 대한바이러스학회지. 1986. 15:1–9.

9). 이연태, 조규봉, 강필원. 1987년일부한국인의일본뇌염바이러스에대한HI 항체분포. 대한바이러스학회지. 1989. 19:41–7.

10). Poland JD., Cropp CB., Craven RB., Monath TP. Evaluation of the potency and safety of inacti- vated Japanese encephalitis vaccine in U.S. inhabitants. J Infect Dis. 1990. 161:878–82.

11). Gambel JM., DeFraites R: Hoke C: Brown A., Karabatsos N: Tsai T, et al. Japanese encephalitis vaccine: Persistence of antibody up to 3 years after a three-dose primary series. J Infect Dis. 1995. 171:1074.

12). Sanchez JL., Hoke CH: McCowan J., DeFraites RF., Takafuji ET., Diniega BM, et al. Further experience with Japanese encephalitis vaccine. Lancet. 1990. 335:972–3.

13). CDC. Inactivation Japanese Encephalitis Virus Vaccine Recommendations of the ACIP. MMWR. 1993. 42:No.RR-l.

14). Tsai TF., Chang GJ., Yu YX. Japanese encephalitis vaccines. In:. Plotkin SA, Qrenstein WA, editors. editors.Vaccines. 3rd ed.Philadelphia: WB. Saunders;1999. p. 672–710.

15). 손영모: 조해월: 김창휘, 오성희: 이환종, 강진한둥. 일본뇌염백신접종후면역항체지속률에대한연구. 감염. 1995. 27:519.

16). 조해월: 남재환: 이호동, 고현철: 김정제, 김은정둥. 일본뇌염백신접종후항일본뇌염항체의생성율과지속적인면역반응에대한연구. 소아감염. 1997. 4:116–25.

17). 손영모. 일본뇌염백신부작용에관한조사보고. 감염. 1994. 26:449.

18). Ohtaki E: Murakami Y., Komori H., Yamashita Y: Matsuishi T. Acute disseminated encephalitis after Japanese B encephalitis vaccination. Pe- diatri Neurol. 1992. 8:137–9.

19). Hoke CH: Nisalak A: Sangawhipa N: Jatanasen S., Laorakapongse T., Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988. 319:608–14.

20). Poland JD., Cropp B: Craven RB., Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants, J Infect Dis. 1990. 161:878–82.

21). Canada Disease Weekly Report. Japanese en- cephalitis vaccine and adverse effects among travelers. 1990. 335:972–3.

22). Australian Adverse Drug Reactions Adivisory Committee. Reactions to J약)anese encephalitis vaccine. ADRAC Rep no 9. 1991.

23). Holoshitz J., Frenkel A., Ben-Nun A., Cohen IR. Autoimmune encephalomyelitis mediated and prevented by T lymphocyte lines directed against diverse antigenic determinants of myelin basic protein. J Immunol. 1983. 131:2810–2.

24). Ruff TA., Eisen D., Fuller A., Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet. 1991. 338:881–2.

25). Racke MK., Quigely L: Cannella B., Raine CS., McFarlin DE., Scott DE. Superantigen modulation of experimental allergic encephalomyelitis. J Immunol. 1994. 152:2051–4.

26). 김훈: 장양석: 안창남, 김희철: 이호왕. 면역효소법을이용한마우스뇌유래의백신에서Myelin basic protein의정량: 한타박스와일본뇌염백신. 대한미생물학회지. 1995. 30:563–71.